Literature DB >> 21144885

Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats.

M Gutiérrez-Fernández1, B Rodríguez-Frutos, J Alvarez-Grech, M T Vallejo-Cremades, M Expósito-Alcaide, J Merino, J M Roda, E Díez-Tejedor.   

Abstract

Hematic administration of bone marrow-derived mesenchymal stem cells (MSCs) in acute ischemic stroke may not only be an effective reparative treatment but also a brain protective therapy that improves neurological recovery. Our purpose was to study whether either i.v. or intracarotid (i.c.) administration of allogenic MSCs during the acute phase were effective in improving neurological recovery and decreasing brain damage in an experimental rat model. In a model of permanent middle cerebral artery occlusion (pMCAO), we analyzed: neurological evaluation; MSCs migration and implantation; interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels; lesion volume; cell death; cellular proliferation; vascular endothelial growth factor (VEGF) expression and blood vessel number. Regardless of the administration route, treated groups showed better neurological recovery, without significant differences between the two groups. Migration and implantation of MSCs in the lesion area was observed in animals receiving i.c. but not i.v. treatment. The highest cytokine values were observed in the i.v. MSCs and i.c. control groups, and these levels were significantly different from the corresponding i.v. control and i.c. MSCs groups, respectively. In addition, there were significant differences between the i.v. MSCs and i.c. MSCs groups in IL-6 levels. Neither treatment reduced infarction volume. However, cell death, measured as TUNEL+ cells was decreased with significant differences between control groups. BrdU+ cells were also significantly increased in the peri-infarct zone at 14 days. VEGF expression was significantly higher in the i.c. MSCs group than in the i.c. control group and blood vessel number was significantly higher in treated groups than control groups with significant differences in the peri-infarct zone at 14 days. We conclude that allogenic MSCs administration shows therapeutic efficacy in our acute ischemic stroke model. Both routes demonstrably improved neurological recovery and provided brain protection. Crown Copyright Â
© 2011. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21144885     DOI: 10.1016/j.neuroscience.2010.11.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  56 in total

1.  Intra-arterial transplantation of low-dose stem cells provides functional recovery without adverse effects after stroke.

Authors:  Yuhtaka Fukuda; Nobutaka Horie; Katsuya Satoh; Susumu Yamaguchi; Youichi Morofuji; Takeshi Hiu; Tsuyoshi Izumo; Kentaro Hayashi; Noriyuki Nishida; Izumi Nagata
Journal:  Cell Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.046

2.  The CCR2/CCL2 interaction mediates the transendothelial recruitment of intravascularly delivered neural stem cells to the ischemic brain.

Authors:  Robert H Andres; Raymond Choi; Arjun V Pendharkar; Xavier Gaeta; Nancy Wang; Jaya K Nathan; Joshua Y Chua; Star W Lee; Theo D Palmer; Gary K Steinberg; Raphael Guzman
Journal:  Stroke       Date:  2011-08-11       Impact factor: 7.914

Review 3.  Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.

Authors:  Antoine Monsel; Ying-Gang Zhu; Stephane Gennai; Qi Hao; Jia Liu; Jae W Lee
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

4.  Exosomes promote restoration after an experimental animal model of intracerebral hemorrhage.

Authors:  Laura Otero-Ortega; Mari Carmen Gómez de Frutos; Fernando Laso-García; Berta Rodríguez-Frutos; Esperanza Medina-Gutiérrez; Juan Antonio López; Jesús Vázquez; Exuperio Díez-Tejedor; María Gutiérrez-Fernández
Journal:  J Cereb Blood Flow Metab       Date:  2017-05-19       Impact factor: 6.200

Review 5.  Human stromal (mesenchymal) stem cells: basic biology and current clinical use for tissue regeneration.

Authors:  Abdullah Aldahmash; Walid Zaher; May Al-Nbaheen; Moustapha Kassem
Journal:  Ann Saudi Med       Date:  2012 Jan-Feb       Impact factor: 1.526

Review 6.  Intra-Arterial Delivery of Cell Therapies for Stroke.

Authors:  Raphael Guzman; Miroslaw Janowski; Piotr Walczak
Journal:  Stroke       Date:  2018-04-18       Impact factor: 7.914

Review 7.  Distal occlusion of the middle cerebral artery in mice: are we ready to assess long-term functional outcome?

Authors:  Anna Rosell; Véronique Agin; Mahbubur Rahman; Anna Morancho; Carine Ali; Jari Koistinaho; Xiaoying Wang; Denis Vivien; Markus Schwaninger; Joan Montaner
Journal:  Transl Stroke Res       Date:  2013-01-09       Impact factor: 6.829

Review 8.  Brain mesenchymal stem cells: The other stem cells of the brain?

Authors:  Florence Appaix; Marie-France Nissou; Boudewijn van der Sanden; Matthieu Dreyfus; François Berger; Jean-Paul Issartel; Didier Wion
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

9.  Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation.

Authors:  Miroslaw Janowski; Agatha Lyczek; Charla Engels; Jiadi Xu; Barbara Lukomska; Jeff W M Bulte; Piotr Walczak
Journal:  J Cereb Blood Flow Metab       Date:  2013-03-13       Impact factor: 6.200

10.  Among mesenchymal stem cells: for the best therapy after ischemic stroke.

Authors:  Yuka Ikegame
Journal:  Stem Cell Res Ther       Date:  2013-01-31       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.